Page last updated: 2024-12-11

9-cis-retinal

Description Research Excerpts Clinical Trials Roles Classes Pathways Study Profile Bioassays Related Drugs Related Conditions Protein Interactions Research Growth Market Indicators

Description

9-cis-retinal : A retinal in which the double bond at position 9 has cis configuration, whilst the remaining acyclic double bonds have trans configuration. [Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res]

Cross-References

ID SourceID
PubMed CID6436082
CHEMBL ID257381
CHEBI ID78273
MeSH IDM0098658

Synonyms (30)

Synonym
einecs 208-188-8
brn 1914180
9-cis-vitamin a aldehyde
9-cis-retinaldehyde
9-cis-3,7-dimethyl-9-(2,6,6-trimethyl-1-cyclohexen-1-yl)-2,4,6,8-nonatetraenal
9-c-retinal
isoretinene a
retinal, 9-cis-
9-cis-retinal
LMPR01090017
514-85-2
iso rhodopsin
chebi:78273 ,
CHEMBL257381
4-07-00-01254 (beilstein handbook reference)
9-cis retinal
gtpl6673
(2e,4e,6z,8e)-3,7-dimethyl-9-(2,6,6-trimethyl-1-cyclohexenyl)nona-2,4,6,8-tetraenal
(9cis)-retinal
(2e,4e,6z,8e)-3,7-dimethyl-9-(2,6,6-trimethylcyclohex-1-en-1-yl)nona-2,4,6,8-tetraenal
9-cis-7,11,13-trans-retinal
retinal #
cis-9-retinal
DTXSID00891233
CS-W010026
Q27074046
HY-W009310
F85600
MS-24056
AKOS040744160
[information is derived through text-mining from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Drug Classes (1)

ClassDescription
retinalAn enal that consists of 3,7-dimethyl-9-nona-2,4,6,8-tetraenal (double bond geometry unspecified) carrying a 2,6,6-trimethylcyclohex-1-en-1-yl group at the 9-position.
[compound class information is derived from Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res]

Pathways (7)

PathwayProteinsCompounds
Signaling Pathways1269117
Signaling by Nuclear Receptors15246
Signaling by Retinoic Acid2431
RA biosynthesis pathway1119
Retinol Metabolism3730
Vitamin A Deficiency3730
Retinol metabolism1812
Vitamin A and carotenoid metabolism020

Protein Targets (2)

Other Measurements

ProteinTaxonomyMeasurementAverageMin (ref.)Avg (ref.)Max (ref.)Bioassay(s)
[prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023]

Biological Processes (17)

Processvia Protein(s)Taxonomy
retinoid metabolic processAldo-keto reductase family 1 member B10Homo sapiens (human)
farnesol catabolic processAldo-keto reductase family 1 member B10Homo sapiens (human)
retinol metabolic processAldo-keto reductase family 1 member B10Homo sapiens (human)
daunorubicin metabolic processAldo-keto reductase family 1 member B10Homo sapiens (human)
doxorubicin metabolic processAldo-keto reductase family 1 member B10Homo sapiens (human)
cellular detoxification of aldehydeAldo-keto reductase family 1 member B10Homo sapiens (human)
retinoid metabolic processAldo-keto reductase family 1 member B1Homo sapiens (human)
epithelial cell maturationAldo-keto reductase family 1 member B1Homo sapiens (human)
renal water homeostasisAldo-keto reductase family 1 member B1Homo sapiens (human)
carbohydrate metabolic processAldo-keto reductase family 1 member B1Homo sapiens (human)
prostaglandin metabolic processAldo-keto reductase family 1 member B1Homo sapiens (human)
C21-steroid hormone biosynthetic processAldo-keto reductase family 1 member B1Homo sapiens (human)
L-ascorbic acid biosynthetic processAldo-keto reductase family 1 member B1Homo sapiens (human)
regulation of urine volumeAldo-keto reductase family 1 member B1Homo sapiens (human)
retinol metabolic processAldo-keto reductase family 1 member B1Homo sapiens (human)
negative regulation of apoptotic processAldo-keto reductase family 1 member B1Homo sapiens (human)
daunorubicin metabolic processAldo-keto reductase family 1 member B1Homo sapiens (human)
doxorubicin metabolic processAldo-keto reductase family 1 member B1Homo sapiens (human)
fructose biosynthetic processAldo-keto reductase family 1 member B1Homo sapiens (human)
cellular hyperosmotic salinity responseAldo-keto reductase family 1 member B1Homo sapiens (human)
metanephric collecting duct developmentAldo-keto reductase family 1 member B1Homo sapiens (human)
[Information is prepared from geneontology information from the June-17-2024 release]

Molecular Functions (14)

Processvia Protein(s)Taxonomy
retinal dehydrogenase activityAldo-keto reductase family 1 member B10Homo sapiens (human)
aldo-keto reductase (NADPH) activityAldo-keto reductase family 1 member B10Homo sapiens (human)
protein bindingAldo-keto reductase family 1 member B10Homo sapiens (human)
alcohol dehydrogenase (NADP+) activityAldo-keto reductase family 1 member B10Homo sapiens (human)
geranylgeranyl reductase activityAldo-keto reductase family 1 member B10Homo sapiens (human)
allyl-alcohol dehydrogenase activityAldo-keto reductase family 1 member B10Homo sapiens (human)
indanol dehydrogenase activityAldo-keto reductase family 1 member B10Homo sapiens (human)
all-trans-retinol dehydrogenase (NADP+) activityAldo-keto reductase family 1 member B10Homo sapiens (human)
aldose reductase (NADPH) activityAldo-keto reductase family 1 member B10Homo sapiens (human)
retinal dehydrogenase activityAldo-keto reductase family 1 member B1Homo sapiens (human)
aldose reductase (NADPH) activityAldo-keto reductase family 1 member B1Homo sapiens (human)
protein bindingAldo-keto reductase family 1 member B1Homo sapiens (human)
electron transfer activityAldo-keto reductase family 1 member B1Homo sapiens (human)
prostaglandin H2 endoperoxidase reductase activityAldo-keto reductase family 1 member B1Homo sapiens (human)
glyceraldehyde oxidoreductase activityAldo-keto reductase family 1 member B1Homo sapiens (human)
allyl-alcohol dehydrogenase activityAldo-keto reductase family 1 member B1Homo sapiens (human)
L-glucuronate reductase activityAldo-keto reductase family 1 member B1Homo sapiens (human)
glycerol dehydrogenase [NADP+] activityAldo-keto reductase family 1 member B1Homo sapiens (human)
all-trans-retinol dehydrogenase (NADP+) activityAldo-keto reductase family 1 member B1Homo sapiens (human)
[Information is prepared from geneontology information from the June-17-2024 release]

Ceullar Components (7)

Processvia Protein(s)Taxonomy
extracellular regionAldo-keto reductase family 1 member B10Homo sapiens (human)
lysosomeAldo-keto reductase family 1 member B10Homo sapiens (human)
cytosolAldo-keto reductase family 1 member B10Homo sapiens (human)
cytosolAldo-keto reductase family 1 member B10Homo sapiens (human)
mitochondrionAldo-keto reductase family 1 member B10Homo sapiens (human)
extracellular spaceAldo-keto reductase family 1 member B1Homo sapiens (human)
nucleoplasmAldo-keto reductase family 1 member B1Homo sapiens (human)
cytosolAldo-keto reductase family 1 member B1Homo sapiens (human)
extracellular exosomeAldo-keto reductase family 1 member B1Homo sapiens (human)
cytosolAldo-keto reductase family 1 member B1Homo sapiens (human)
[Information is prepared from geneontology information from the June-17-2024 release]

Bioassays (14)

Assay IDTitleYearJournalArticle
AID318823Activity of human AKR1B1 by BSA/HPLC method2007Proceedings of the National Academy of Sciences of the United States of America, Dec-26, Volume: 104, Issue:52
Structural basis for the high all-trans-retinaldehyde reductase activity of the tumor marker AKR1B10.
AID318825Activity of human wild type AKR1B10 by BSA/HPLC method2007Proceedings of the National Academy of Sciences of the United States of America, Dec-26, Volume: 104, Issue:52
Structural basis for the high all-trans-retinaldehyde reductase activity of the tumor marker AKR1B10.
AID318829Activity of human AKR1B10 V301L mutant by BSA/HPLC method2007Proceedings of the National Academy of Sciences of the United States of America, Dec-26, Volume: 104, Issue:52
Structural basis for the high all-trans-retinaldehyde reductase activity of the tumor marker AKR1B10.
AID318831Activity of human AKR1B10 K125L/V301L mutant by BSA/HPLC method2007Proceedings of the National Academy of Sciences of the United States of America, Dec-26, Volume: 104, Issue:52
Structural basis for the high all-trans-retinaldehyde reductase activity of the tumor marker AKR1B10.
AID515688Induction of subcellular localization of HA-tagged human rhodopsin P23H mutant on HEK293 cell surface by immunofluorescence microscopy2010Bioorganic & medicinal chemistry, Oct-01, Volume: 18, Issue:19
Retinobenzaldehydes as proper-trafficking inducers of folding-defective P23H rhodopsin mutant responsible for retinitis pigmentosa.
AID318832Ratio of Kcat to Km for human AKR1B10 K125L/V301L mutant2007Proceedings of the National Academy of Sciences of the United States of America, Dec-26, Volume: 104, Issue:52
Structural basis for the high all-trans-retinaldehyde reductase activity of the tumor marker AKR1B10.
AID515689Cytotoxicity against HEK293 cells by WST-1 assay2010Bioorganic & medicinal chemistry, Oct-01, Volume: 18, Issue:19
Retinobenzaldehydes as proper-trafficking inducers of folding-defective P23H rhodopsin mutant responsible for retinitis pigmentosa.
AID318826Ratio of Kcat to Km for human wild type AKR1B102007Proceedings of the National Academy of Sciences of the United States of America, Dec-26, Volume: 104, Issue:52
Structural basis for the high all-trans-retinaldehyde reductase activity of the tumor marker AKR1B10.
AID318827Activity of human AKR1B10 K125L mutant by BSA/HPLC method2007Proceedings of the National Academy of Sciences of the United States of America, Dec-26, Volume: 104, Issue:52
Structural basis for the high all-trans-retinaldehyde reductase activity of the tumor marker AKR1B10.
AID318830Ratio of Kcat to Km for human AKR1B10 V301L mutant2007Proceedings of the National Academy of Sciences of the United States of America, Dec-26, Volume: 104, Issue:52
Structural basis for the high all-trans-retinaldehyde reductase activity of the tumor marker AKR1B10.
AID591677Agonist activity at bovine rhodopsin assessed as opsin mediated cognate G protein transducer activation by fluorescence assay2011Journal of natural products, Mar-25, Volume: 74, Issue:3
Cyclopropyl and isopropyl derivatives of 11-cis and 9-cis retinals at C-9 and C-13: subtle steric differences with major effects on ligand efficacy in rhodopsin.
AID318828Ratio of Kcat to Km for human AKR1B10 K125L mutant2007Proceedings of the National Academy of Sciences of the United States of America, Dec-26, Volume: 104, Issue:52
Structural basis for the high all-trans-retinaldehyde reductase activity of the tumor marker AKR1B10.
AID515690Upregulation of HA-tagged rhodopsin P23H expression in HEK293 cell surface by ELISA2010Bioorganic & medicinal chemistry, Oct-01, Volume: 18, Issue:19
Retinobenzaldehydes as proper-trafficking inducers of folding-defective P23H rhodopsin mutant responsible for retinitis pigmentosa.
AID318824Ratio of Kcat to Km for human AKR1B12007Proceedings of the National Academy of Sciences of the United States of America, Dec-26, Volume: 104, Issue:52
Structural basis for the high all-trans-retinaldehyde reductase activity of the tumor marker AKR1B10.
[information is prepared from bioassay data collected from National Library of Medicine (NLM), extracted Dec-2023]

Research

Studies (74)

TimeframeStudies, This Drug (%)All Drugs %
pre-19902 (2.70)18.7374
1990's10 (13.51)18.2507
2000's27 (36.49)29.6817
2010's29 (39.19)24.3611
2020's6 (8.11)2.80
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Market Indicators

Research Demand Index: 28.59

According to the monthly volume, diversity, and competition of internet searches for this compound, as well the volume and growth of publications, there is estimated to be moderate demand-to-supply ratio for research on this compound.

MetricThis Compound (vs All)
Research Demand Index28.59 (24.57)
Research Supply Index4.33 (2.92)
Research Growth Index5.30 (4.65)
Search Engine Demand Index31.18 (26.88)
Search Engine Supply Index2.00 (0.95)

This Compound (28.59)

All Compounds (24.57)

Study Types

Publication TypeThis drug (%)All Drugs (%)
Trials0 (0.00%)5.53%
Reviews0 (0.00%)6.00%
Case Studies0 (0.00%)4.05%
Observational0 (0.00%)0.25%
Other75 (100.00%)84.16%
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]